CL2018003050A1 - Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. - Google Patents
Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas.Info
- Publication number
- CL2018003050A1 CL2018003050A1 CL2018003050A CL2018003050A CL2018003050A1 CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1 CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- angle
- wnt
- disorders
- signaling
- Prior art date
Links
- KKSZSACCVDIWIE-UHFFFAOYSA-N isoquinoline-3-carboxamide Chemical class C1=CC=C2C=NC(C(=O)N)=CC2=C1 KKSZSACCVDIWIE-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- -1 ISOQUINOLINE COMPOUND Chemical class 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328210P | 2016-04-27 | 2016-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003050A1 true CL2018003050A1 (es) | 2019-01-25 |
Family
ID=60157342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003050A CL2018003050A1 (es) | 2016-04-27 | 2018-10-26 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. |
| CL2019002067A CL2019002067A1 (es) | 2016-04-27 | 2019-07-24 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002067A CL2019002067A1 (es) | 2016-04-27 | 2019-07-24 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050). |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10508099B2 (enExample) |
| EP (2) | EP3448838B1 (enExample) |
| JP (1) | JP7023243B2 (enExample) |
| KR (1) | KR102399206B1 (enExample) |
| CN (1) | CN109311819B (enExample) |
| AR (1) | AR108326A1 (enExample) |
| AU (1) | AU2017258187B2 (enExample) |
| BR (1) | BR112018072190A2 (enExample) |
| CA (1) | CA3022044A1 (enExample) |
| CL (2) | CL2018003050A1 (enExample) |
| CO (1) | CO2018012655A2 (enExample) |
| IL (1) | IL262495B (enExample) |
| MA (1) | MA43605B1 (enExample) |
| MX (1) | MX386319B (enExample) |
| PE (1) | PE20190260A1 (enExample) |
| PH (1) | PH12018502259A1 (enExample) |
| RU (1) | RU2018141379A (enExample) |
| SG (2) | SG10201914127PA (enExample) |
| WO (1) | WO2017189823A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
| US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
| US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
| US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151501A1 (es) | 2012-12-21 | 2015-11-08 | Epizyme Inc | Inhibidores de prmt5 y sus usos |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| JP7160688B2 (ja) * | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
| US11149022B2 (en) * | 2017-10-17 | 2021-10-19 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| WO2019084496A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE |
| WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
| JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| CN114401946A (zh) * | 2019-09-05 | 2022-04-26 | 鲁南制药集团股份有限公司 | Magl抑制剂及其制备方法、用途 |
| IL299080A (en) * | 2020-06-19 | 2023-02-01 | Univ Vanderbilt | Arylsulfonyl history and their use as M5 muscarinic acetylcholine receptor inhibitors |
| WO2022093881A1 (en) * | 2020-10-29 | 2022-05-05 | Merck Sharp & Dohme Corp. | N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| TW202302565A (zh) * | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| WO2023055679A1 (en) * | 2021-10-01 | 2023-04-06 | Merck Sharp & Dohme Llc | C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| WO2023107714A2 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Methods for treating neurological disorders |
| TW202506660A (zh) * | 2023-04-27 | 2025-02-16 | 美商塞普特納公司 | Mrgprx2拮抗劑及其使用方法 |
| KR20240162928A (ko) | 2023-05-09 | 2024-11-18 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| ES2131463B1 (es) * | 1997-04-08 | 2000-03-01 | Lilly Sa | Derivados de ciclopropilglicina con propiedades farmaceuticas. |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2008537684A (ja) | 2005-01-24 | 2008-09-25 | ニューロシステック コーポレイション | 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法 |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| AU2008287435B2 (en) | 2007-08-15 | 2013-05-16 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| JP2013501792A (ja) | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 |
| DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
| RU2012146246A (ru) * | 2010-03-31 | 2014-05-10 | Актелион Фармасьютиклз Лтд | Антибактериальные производные изохинолин-3-илмочевины |
| EA026115B1 (ru) | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| PT2755483T (pt) | 2011-09-14 | 2019-02-18 | Samumed Llc | Indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização de wnt/β-catenina |
| WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
-
2017
- 2017-04-26 AR ARP170101056A patent/AR108326A1/es unknown
- 2017-04-27 EP EP17790411.7A patent/EP3448838B1/en active Active
- 2017-04-27 EP EP21181038.7A patent/EP3943086A1/en not_active Withdrawn
- 2017-04-27 SG SG10201914127PA patent/SG10201914127PA/en unknown
- 2017-04-27 PE PE2018002175A patent/PE20190260A1/es unknown
- 2017-04-27 AU AU2017258187A patent/AU2017258187B2/en not_active Ceased
- 2017-04-27 BR BR112018072190-5A patent/BR112018072190A2/pt not_active IP Right Cessation
- 2017-04-27 JP JP2018556921A patent/JP7023243B2/ja active Active
- 2017-04-27 RU RU2018141379A patent/RU2018141379A/ru unknown
- 2017-04-27 CA CA3022044A patent/CA3022044A1/en active Pending
- 2017-04-27 US US15/498,990 patent/US10508099B2/en active Active
- 2017-04-27 MA MA43605A patent/MA43605B1/fr unknown
- 2017-04-27 SG SG11201809310PA patent/SG11201809310PA/en unknown
- 2017-04-27 KR KR1020187034080A patent/KR102399206B1/ko active Active
- 2017-04-27 WO PCT/US2017/029797 patent/WO2017189823A2/en not_active Ceased
- 2017-04-27 CN CN201780037470.7A patent/CN109311819B/zh active Active
- 2017-04-27 MX MX2018013173A patent/MX386319B/es unknown
-
2018
- 2018-03-19 US US15/925,157 patent/US10287267B2/en active Active
- 2018-04-03 US US15/943,864 patent/US10556885B2/en active Active
- 2018-10-21 IL IL262495A patent/IL262495B/en unknown
- 2018-10-23 PH PH12018502259A patent/PH12018502259A1/en unknown
- 2018-10-26 CL CL2018003050A patent/CL2018003050A1/es unknown
- 2018-11-23 CO CONC2018/0012655A patent/CO2018012655A2/es unknown
-
2019
- 2019-07-24 CL CL2019002067A patent/CL2019002067A1/es unknown
- 2019-12-26 US US16/727,053 patent/US11174244B2/en active Active
-
2021
- 2021-10-06 US US17/495,281 patent/US11673881B2/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
| US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
| US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
| US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003050A1 (es) | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. | |
| CL2019001343A1 (es) | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065) | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018002794A1 (es) | Compuestos bicíclicos | |
| AR128259A2 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| MX2018013495A (es) | Moduladores de la via de estres integrada. | |
| BR112018003634A8 (pt) | Processo para preparar um inibidor parp, formas cristalinas e usos destes | |
| MX2018003058A (es) | Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas. | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2019013645A (es) | Inhibidores de quinasa y usos de los mismos. | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
| CL2019003213A1 (es) | Compuestos plaguicidas bicíclicos. | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| CL2016002089A1 (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2020002177A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas | |
| CR20160133A (es) | Derivados de fenilalanina sustituidos | |
| MX378739B (es) | Compuestos de 2-oxindol. |